Bormioli Pharma has partnered with research-focused biopharmaceutical company Chiesi for the supply of Carbon Capture polyethylene terephthalate (PET) bottles.
The bottles will be used for packaging a medication that is intended for prophylaxis and treatment of various types of rhinitis.
Go deeper with GlobalData
They offer a 21.9% reduction in carbon dioxide (CO₂) emissions compared to traditional PET without compromising on safety, as the extractables’ levels are similar to those found in standard PET.
The production of Carbon Capture PET involves a unique process where carbon emissions are captured and converted into BioMEG, a crucial component for making PET, through fermentation.
These bottles are recyclable and retain the mechanical and physical properties of conventional PET.
This supply partnership represents the first time a Carbon Capture bottle will be used for pharmaceutical purposes, Bormioli Pharma said in a statement.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataBormioli Pharma CEO Andrea Lodetti said: “The agreement we’ve reached with Chiesi to supply one of their products with Carbon Capture PET bottles demonstrates both the performance and safety of these containers, as well as the growing commitment of the pharma industry towards sustainability.
“For Bormioli Pharma, this is another significant recognition of the high-quality standards achieved by our packaging solutions.
“As of today, almost half of our sales are made up of products manufactured with low-impact materials, thanks to the development of one of the widest sustainable packaging offerings available in the pharma industry, EcoPositive, which comprises over 3,000 items in glass or plastic.”
The EcoPositive product line has seen a 304% volume increase in low-impact plastic containers since 2021 and is progressing towards achieving the company’s ’50-in-5′ corporate strategy.
This strategy aims to have 50% of products sold made from sustainable materials by 2025.
The share was claimed to be 45% as of 2023, which increased to nearly 47% in the first half of 2024.
This advancement is supported by LanzaTech Global and Plastipak, two companies in the sustainable solutions market.
